Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) shares rose 4.3% during mid-day trading on Tuesday. The company traded as high as $16.61 and last traded at $16.59. 2,536,234 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 2,907,005 shares. The stock had previously closed at $15.90.
Analyst Ratings Changes
Several equities analysts have weighed in on RARE shares. Wedbush decreased their target price on shares of Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a "neutral" rating on the stock in a report on Wednesday, November 4th. UBS Group assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, October 15th. They set a "neutral" rating and a $16.00 price target on the stock. Evercore cut Ultragenyx Pharmaceutical from an "outperform" rating to an "in-line" rating and set a $16.00 price objective on the stock. in a report on Thursday, September 3rd. JPMorgan Chase & Co. lowered Ultragenyx Pharmaceutical from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $80.00 to $36.00 in a research report on Thursday, September 3rd. Finally, Royal Bank Of Canada downgraded Ultragenyx Pharmaceutical from a "moderate buy" rating to a "hold" rating in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $29.79.
Read Our Latest Report on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Stock Performance
The stock has a market cap of $1.70 billion, a PE ratio of -3.22 and a beta of 0.37. The firm's 50-day moving average is $15.30 and its 200 day moving average is $22.48.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by ($0.06). The business had revenue of $173.00 million for the quarter, compared to the consensus estimate of $182.49 million. During the same quarter in the previous year, the company posted ($1.81) EPS. The business's revenue for the quarter was up 8.2% compared to the same quarter last year. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -3.21 EPS for the current fiscal year.
Insiders Place Their Bets
In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer directly owned 89,229 shares in the company, valued at approximately $1,362,526.83. This trade represents a 7.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 8,510 shares of company stock worth $127,561. 5.20% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
A number of hedge funds and other institutional investors have recently bought and sold shares of RARE. Aquatic Capital Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 703.9% in the third quarter. Aquatic Capital Management LLC now owns 134,737 shares of the biopharmaceutical company's stock valued at $2,025,000 after acquiring an additional 117,977 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Ultragenyx Pharmaceutical by 201.5% in the third quarter. Goldman Sachs Group Inc. now owns 1,915,608 shares of the biopharmaceutical company's stock valued at $28,792,000 after purchasing an additional 1,280,270 shares during the period. Toronto Dominion Bank lifted its position in Ultragenyx Pharmaceutical by 192.8% in the third quarter. Toronto Dominion Bank now owns 1,215,000 shares of the biopharmaceutical company's stock valued at $18,261,000 after purchasing an additional 800,000 shares during the period. Entropy Technologies LP boosted its holdings in Ultragenyx Pharmaceutical by 170.7% in the 3rd quarter. Entropy Technologies LP now owns 120,042 shares of the biopharmaceutical company's stock valued at $1,804,000 after purchasing an additional 75,697 shares in the last quarter. Finally, Jump Financial LLC boosted its holdings in Ultragenyx Pharmaceutical by 145.6% in the 3rd quarter. Jump Financial LLC now owns 704,752 shares of the biopharmaceutical company's stock valued at $10,592,000 after purchasing an additional 417,800 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.
Ultragenyx Pharmaceutical Company Profile
(
Get Free Report)
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.
While Ultragenyx Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.